BAJAJHCARE Bajaj Healthcare Q1 FY27 results (Apr–Jun 2026) and concall
Bajaj Healthcare Limited reported a strong Q1 FY27, with revenue growing 11.3% YoY to INR165.6 crores and PAT increasing 14.1% YoY. The company demonstrated margin expansion and significant deleveraging. Strategic initiatives in high-value APIs like Peptides and Oncology are progressing, with new facilities and product launches planned, supported by increased R&D investment and backward integration efforts.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 11.4%, net profit up 16.7% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|
| Revenue | 123 | 154 | 149 | 148 | 161 +31% | 153 −1% | 166 +11% |
| EBITDA | 22 | 12 | 25 | 27 | 31 +41% | 23 +92% | 29 +16% |
| Net profit | 12 | 11 | 12 | 11 | 16 +33% | -23 −309% | 14 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
